{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:12:28Z","timestamp":1773681148067,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T00:00:00Z","timestamp":1441756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Reumatologia"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.rbr.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T14:53:16Z","timestamp":1443279196000},"page":"512-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide"],"prefix":"10.1186","volume":"55","author":[{"given":"Licia Maria Henrique da","family":"Mota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00f3ris Afonso","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleandro Pires de","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah Pereira","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieda Maria Magalh\u00e3es","family":"Laurindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivanio Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joz\u00e9lio Freire de","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldo da Rocha Castelar","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoel Barros","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Raquel da Costa","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Louzada\u2010Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Machado","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina Dalva Neubarth","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Aires Corr\u00eaa","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"3","key":"10.1016\/j.rbr.2015.08.004_bib0230","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease\u2010modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rbr.2015.08.004_bib0235","first-page":"199","article-title":"2011 Consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of rheumatoid arthritis","volume":"51","author":"da Mota","year":"2011","journal-title":"Rev Bras Reumatol"},{"issue":"2","key":"10.1016\/j.rbr.2015.08.004_bib0240","first-page":"152","article-title":"2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis","volume":"52","author":"da Mota","year":"2012","journal-title":"Rev Bras Reumatol"},{"issue":"4","key":"10.1016\/j.rbr.2015.08.004_bib0245","first-page":"474","article-title":"2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis","volume":"52","author":"Pereira","year":"2012","journal-title":"Rev Bras Reumatol"},{"issue":"2","key":"10.1016\/j.rbr.2015.08.004_bib0250","first-page":"158","article-title":"Guidelines for the drug treatment of rheumatoid arthritis","volume":"53","author":"Mota","year":"2013","journal-title":"Rev Bras Reumatol."},{"issue":"Suppl 2","key":"10.1016\/j.rbr.2015.08.004_bib0255","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbr.2015.08.004_bib0260","unstructured":"Di\u00e1rio Oficial da Uni\u00e3o \u2010Suplemento Anvisa\u2013DOU1\u2013Edi\u00e7\u00e3o nr 237 de 08\/12\/2014 Pag. 13. Dispon\u00edvel em: http:\/\/pesquisa.in.gov.br\/imprensa\/jsp\/visualiza\/index.jsp?jornal=1010&pagina=13&data=08\/12\/2014 [Acessado em 19\/06\/2015]."},{"key":"10.1016\/j.rbr.2015.08.004_bib0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak."},{"issue":"4","key":"10.1016\/j.rbr.2015.08.004_bib0270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease\u2010modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med."},{"issue":"6","key":"10.1016\/j.rbr.2015.08.004_bib0275","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.rbr.2015.08.004_bib0280","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP\u2010690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve\u2010month data from a twenty\u2010four\u2010month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"9865","key":"10.1016\/j.rbr.2015.08.004_bib0285","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP\u2010690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.rbr.2015.08.004_bib0290","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo\u2010controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.rbr.2015.08.004_bib0295","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rbr.2015.08.004_bib0300","unstructured":"Bula XELJANZ, Citrato de Tofacitinibe. 2014."},{"issue":"2","key":"10.1016\/j.rbr.2015.08.004_bib0305","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10067-013-2452-7","article-title":"Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease\u2010modifying antirheumatic drug (MMCD): a systematic review and meta\u2010analysis","volume":"33","author":"Zhang","year":"2014","journal-title":"Clin Rheumatol [Internet]."},{"issue":"5","key":"10.1016\/j.rbr.2015.08.004_bib0310","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3904\/kjim.2014.29.5.656","article-title":"Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease\u2010modifying antirheumatic drugs: a meta\u2010analysis of randomized controlled trials","volume":"29","author":"Song","year":"2014","journal-title":"Korean J Intern Med [Internet]."},{"key":"10.1016\/j.rbr.2015.08.004_bib0315","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2474-14-332","article-title":"Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti\u2010rheumatic drugs: a meta\u2010analysis of randomized double\u2010blind controlled studies","volume":"14","author":"Berhan","year":"2013","journal-title":"BMC Musculoskelet Disord [Internet]."},{"key":"10.1016\/j.rbr.2015.08.004_bib0320","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2474-14-298","article-title":"Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta\u2010analysis","volume":"14","author":"He","year":"2013","journal-title":"BMC Musculoskelet Disord [Internet]."},{"issue":"10","key":"10.1016\/j.rbr.2015.08.004_bib0325","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-013-2329-9","article-title":"The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta\u2010analysis","volume":"32","author":"Kawalec","year":"2013","journal-title":"Clin Rheumatol [Internet]."},{"issue":"7","key":"10.1016\/j.rbr.2015.08.004_bib0330","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","article-title":"Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis","volume":"36","author":"Kaur","year":"2014","journal-title":"Clin Ther [Internet]."},{"issue":"7","key":"10.1016\/j.rbr.2015.08.004_bib0335","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double\u2010blind, placebo\u2010controlled phase IIa trial of three dosage levels of CP\u2010690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum [Internet]."},{"issue":"4","key":"10.1016\/j.rbr.2015.08.004_bib0340","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose\u2010ranging study of the oral JAK inhibitor tofacitinib (CP\u2010690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum [Internet]."},{"issue":"Suppl 10","key":"10.1016\/j.rbr.2015.08.004_bib0345","first-page":"2192","article-title":"Tofacitinib (CP\u2010690,550), an oral Janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12\u2010week phase 2b study [abstract]","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.rbr.2015.08.004_bib0350","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP\u2010690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken) [Internet]."},{"key":"10.1016\/j.rbr.2015.08.004_bib0355","first-page":"1","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12\u2010week, randomized, phase 2 study","author":"Tanaka","year":"2014","journal-title":"Mod Rheumatol [Internet]."},{"issue":"3","key":"10.1016\/j.rbr.2015.08.004_bib0360","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose\u2010ranging study of the oral JAK inhibitor tofacitinib (CP\u2010690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease\u2010modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum [Internet]."},{"issue":"2","key":"10.1016\/j.rbr.2015.08.004_bib0365","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/ard.2009.108159","article-title":"Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP\u2010690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double\u2010blind, placebo\u2010controlled trial","volume":"69","author":"Coombs","year":"2010","journal-title":"Ann Rheum Dis [Internet]."},{"issue":"9","key":"10.1016\/j.rbr.2015.08.004_bib0370","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1177\/0091270010379809","article-title":"A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP\u2010690,550) does not prolong QTc interval in healthy participants","volume":"51","author":"Krishnaswami","year":"2011","journal-title":"J Clin Pharmacol [Internet]."},{"issue":"2","key":"10.1016\/j.rbr.2015.08.004_bib0375","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2125.2009.03570.x","article-title":"Co\u2010administration of the JAK inhibitor CP\u2010690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment","volume":"69","author":"Cohen","year":"2010","journal-title":"Br J Clin Pharmacol [Internet]."},{"issue":"suppl","key":"10.1016\/j.rbr.2015.08.004_bib0380","first-page":"S1049","article-title":"Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate\u2010na\u00efve patients with rheumatoid arthritis [Abstract]","volume":"64","author":"Lee","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.rbr.2015.08.004_bib0385","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open\u2010label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol [Internet]."},{"issue":"11","key":"10.1016\/j.rbr.2015.08.004_bib0390","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/infdis\/jis269","article-title":"Risk of tuberculosis reactivation with tofacitinib (CP\u2010690550)","volume":"205","author":"Maiga","year":"2012","journal-title":"J Infect Dis [Internet]."},{"issue":"2","key":"10.1016\/j.rbr.2015.08.004_bib0395","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.30107","article-title":"The incidence of gastrointestinal perforations among rheumatoid arthritis patients","volume":"63","author":"Curtis","year":"2011","journal-title":"Arthritis Rheum [Internet]."},{"issue":"12","key":"10.1016\/j.rbr.2015.08.004_bib0400","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/acr.21764","article-title":"Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res (Hoboken) [Internet]."},{"issue":"4","key":"10.1016\/j.rbr.2015.08.004_bib0405","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5312\/wjo.v5.i4.504","article-title":"Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis","volume":"5","author":"Lundquist","year":"2014","journal-title":"World J Orthop [Internet]."},{"issue":"1","key":"10.1016\/j.rbr.2015.08.004_bib0410","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta\u2010analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ) [Internet]"},{"key":"10.1016\/j.rbr.2015.08.004_bib0415","doi-asserted-by":"crossref","unstructured":"Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, Soma K, Wang L, Riese R. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2015 Apr 22. pii: annrheumdis\u20102014\u2010205847. doi: 10.1136\/annrheumdis\u20102014\u2010205847 [Acessado em 05\/06\/2015].","DOI":"10.1136\/annrheumdis"},{"key":"10.1016\/j.rbr.2015.08.004_bib0420","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.22453","article-title":"Gruben D and Wallenstein Tofacitinib with methotrexate in third\u2010line treatment of patients with active rheumatoid arthritis: patient\u2010reported outcomes from a phase III trial","volume":"67","author":"Strand","year":"2015","journal-title":"Arthritis Care & Research"},{"issue":"10","key":"10.1016\/j.rbr.2015.08.004_bib0425","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.rbr.2015.08.004_bib0430","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rbr.2015.08.004_bib0435","unstructured":"Pileggi GS, Ballalai I, Brenol C, et al. Guia de Imuniza\u00e7\u00e3o SBIm\/SBR\u2013Reumatologia. 2014\/15."},{"issue":"1","key":"10.1016\/j.rbr.2015.08.004_bib0440","first-page":"4","article-title":"2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis","volume":"53","author":"Brenol","year":"2013","journal-title":"Rev Bras Reumatol."},{"issue":"5","key":"10.1016\/j.rbr.2015.08.004_bib0445","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease\u2010modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"RR\u20105","key":"10.1016\/j.rbr.2015.08.004_bib0450","first-page":"1","article-title":"(CDC) ACoIPACfDCaP. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep."}],"container-title":["Revista Brasileira de Reumatologia"],"original-title":[],"language":"pt","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0482500415001278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0482500415001278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T13:19:20Z","timestamp":1514899160000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0482500415001278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0482500415001278"],"URL":"https:\/\/doi.org\/10.1016\/j.rbr.2015.08.004","relation":{},"ISSN":["0482-5004"],"issn-type":[{"value":"0482-5004","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Reumatologia","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.rbr.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}